Skip to main content
. 2019 Dec 9;116(52):26580–26590. doi: 10.1073/pnas.1911273116

Fig. 1.

Fig. 1.

Patient-derived organoids can be established from different pancreatic tumor types and recapitulate the tissue of the original tumor. (A) Pie chart depicting the characteristics of the tumor biobank described in this work. ACC, acinar cell carcinoma; CC, cholangiocarcinoma; IPMN, intraductal papillary mucinous neoplasm. (B) Brightfield images of 3 PDO cultures, shown in 2 magnifications. (C) Brightfield images of H&E staining of tumor tissue and corresponding organoids showing organoid morphology in culture. (D) IHC staining for TP53 in tumor tissue and corresponding organoids of patient 11. The TP53 staining is consistent with TP53 mutation status of the tumor and organoids and is corresponding in tumor tissue and organoids. (E) IHC for SMAD4 in tumor tissue and brightfield images of corresponding organoid lines, grown in either complete medium or medium lacking A83-01 and Noggin. SMAD4 mutant cells can be functionally selected in organoid cultures by removing TGF-β inhibitors A83-01 and Noggin. (F) qPCR for BMP target genes ID1 and ID3. Induction of BMP signaling by the removal of Noggin and A83-01 resulted in up-regulation of ID1 and ID3 in SMAD4 wild-type PDO 8 and PDO 10 but not in SMAD mutant PDO 23. Expression is shown relative to organoids grown in complete medium. This experiment was performed in technical triplicate.